Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.
about
Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.Novel methodology to evaluate renal cysts in polycystic kidney disease.Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease.Automatic Segmentation of Kidneys using Deep Learning for Total Kidney Volume Quantification in Autosomal Dominant Polycystic Kidney Disease.Hypertension in autosomal dominant polycystic kidney disease.Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study.Predictors of autosomal dominant polycystic kidney disease progressionAutosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney diseaseMagnetic resonance imaging of kidney and cyst volume in children with ADPKD.Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participantsImaging approaches to patients with polycystic kidney disease.Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2).A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney diseaseKidney volume and functional outcomes in autosomal dominant polycystic kidney disease.2-Hydroxyestradiol slows progression of experimental polycystic kidney diseaseAssessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.Optimal care of autosomal dominant polycystic kidney disease patients.Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression.Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease.Developments in the management of autosomal dominant polycystic kidney disease.Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study.MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancementCaffeine intake by patients with autosomal dominant polycystic kidney disease.Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images.Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.Polycystic kidney disease: pathogenesis and potential therapies.Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease.Review of tolvaptan for autosomal dominant polycystic kidney disease.Rationale for early treatment of polycystic kidney disease.An approach to cystic kidney diseases: the clinician's view.An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.Renal and extrarenal manifestations of autosomal dominant polycystic kidney disease.Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
P2860
Q33571813-CA0D200D-BFD3-42EC-9803-E2FE0023CABBQ33609117-575F3D05-9620-4640-A727-BD14EFC86698Q33611859-3781CA81-002C-477D-94E1-4FF7E14DCD40Q33700489-206A7EB0-5B65-4F9D-9EDE-49C2C0E632A3Q33754691-8242EEE3-CF5C-4D77-80FB-20F325E3E78AQ33820977-C1732EC6-D356-4012-8FA7-224C8EB2BDC0Q34398335-6A804B37-204D-4B5E-919E-55755D2A4E55Q34427678-4D628353-D97B-4034-9E71-D451D6FBB608Q34467747-4C77EFF0-D2AE-42CD-A321-AFC8C3587A5FQ34600282-E18EFC0B-173B-4055-9456-571BEFE93FA4Q34639673-E2FD0E74-9B1E-4345-BEFC-6B12F32393D2Q34796003-118A4FEE-E306-4DC1-AACE-03C2B9484C08Q35127313-94F4F4A7-F33C-4203-9AC5-9E0609AFC160Q35267170-F65EA084-AE9A-45BC-924B-7AA20BB21110Q35661408-07E0C86A-7346-4F8F-B596-DE03DB071233Q35812435-2DFD1B2E-BB66-4679-A515-3479506D3FA4Q35827271-B9208F67-E3C5-45C0-A981-526AE25C3056Q35964504-0F17E4FF-0E24-4C36-B494-DD34D0B1D8E4Q36315686-273FA8DE-C6F9-480B-82C9-9643EEF91464Q36466760-16B4F641-8333-44D7-8949-24D21124E1E3Q36497881-D7C5B2D8-47CB-44FB-935C-B9C94D1CF9BDQ36741005-167FD3B7-D706-41F9-B44A-0F7819D939D9Q36770909-E75DD6EB-2689-4DD2-B9F5-CB045A237304Q36823578-A2622F0F-8030-4DAF-ACEB-C11368A1ABA5Q36906107-6977C924-305E-4854-917C-9FF6DDAB3F24Q37152523-B5FE1629-53A7-48A8-A6B6-7F71FF200A03Q37371261-B2689AEB-B617-44B2-A969-BEACEE9599F5Q37646799-00A25DB0-6C69-4D50-8E42-E3B70EC6EA21Q37693993-B4373484-64CD-490C-A2C6-D167393710B5Q37697510-AD73B5B9-35FC-4A3F-BCD7-B1CC82D2D946Q37819164-86B320E3-45D3-47B7-8926-BCEAE92FF916Q38030726-B5C83C86-89D6-49AD-9B53-5B4D20500031Q38067358-95EA7EFA-F728-4FE5-968D-6227597B0066Q38202613-A27164FF-ABF6-4085-AAFF-5E8671DFB987Q38229242-4E41BC8E-E499-49D8-9607-47AC72242565Q38255292-0E6B3FD8-5406-41BA-802A-10033A78A9D6Q38540557-C7524A32-C4B6-452D-9CBB-20947008F174Q38760605-49A65655-54CF-4920-8216-ECBE8C3588CDQ39751714-A5C6435E-8F06-4542-9BCD-0D954C4D43FFQ41823915-56F5DD72-C810-49DC-9DE2-A43E774955B0
P2860
Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Relationship between renal vol ...... disease: a longitudinal study.
@en
Relationship between renal vol ...... disease: a longitudinal study.
@nl
type
label
Relationship between renal vol ...... disease: a longitudinal study.
@en
Relationship between renal vol ...... disease: a longitudinal study.
@nl
prefLabel
Relationship between renal vol ...... disease: a longitudinal study.
@en
Relationship between renal vol ...... disease: a longitudinal study.
@nl
P2093
P356
P1476
Relationship between renal vol ...... disease: a longitudinal study.
@en
P2093
Ann M Johnson
Godela M Fick-Brosnahan
Kim K McFann
Mark M Belz
P304
P356
10.1053/AJKD.2002.33379
P577
2002-06-01T00:00:00Z